No Data
No Data
Buy Rating for CG Oncology, Inc.: Promising Efficacy and Competitive Positioning in NMIBC Treatment
CG Oncology to Hold a Conference Call
CG Oncology Announces Phase 3 BOND-003 Data Presented at AUA Meeting
Express News | CG Oncology Inc - No Grade 3 or Greater Adverse Events Reported
Express News | CG Oncology Inc - 97.3% Patients Free From Mibc Progression at 24 Months
Express News | CG Oncology Inc - Cretostimogene Monotherapy Shows 42.3% Response Rate at 24 Months